

Introduction

The purpose of issuing Hypertension Clinical Practice Guidelines is to improve cardiovascular care through evidence-based management of hypertension across the defined population. The defined population is non-pregnant adults, 18 years or older, who do not have diabetes, heart failure, renal insufficiency, or known coronary heart disease. The guidelines also address treatment of two discrete populations: women of childbearing potential and post-stroke patients. Finally, the guidelines address home monitoring of hypertension, aspirin as adjunctive therapy, and anti-lipemic therapy in hypertensive patients.

The guidelines were created by an interregional team organized by the Care Management Institute using an evidence-based methodology. The recommendations are based on the current evidence from randomized, controlled trials and meta-analyses of those studies. When high-quality evidence is not available, recommendations are made on the basis of consensus reached after literature review.

The Importance of Hypertension Control

Controlling hypertension is a very effective way of decreasing the incidence of strokes (CVAs) and myocardial infarctions (MIs) in KP. This is reflected in the numbers needed to treat (NNTs) of **63 for CVAs and 86 for MIs**, for all adults. The **NNT is 36** for the combined end-point of CVA plus MI for all adults.

WHEN TO SCREEN FOR HYPERTENSION

The U.S. Preventive Services Task Force (USPSTF) strongly recommends that clinicians screen adults aged 18 and older for hypertension.

HOW OFTEN TO SCREEN FOR HYPERTENSION

Blood pressure screening every two years is recommended.

Treatment of Hypertension

WHEN TO BEGIN PHARMACOTHERAPY FOR HYPERTENSION

In addition to lifestyle interventions, the following are recommended:

Disclaimer

These Clinical Practice Guidelines are provided as a community service for reference purposes only, and may be used only in conjunction with the caveats set forth in this disclaimer.

These Clinical Practice Guidelines are designed for use by clinicians within the Kaiser Permanente Medical Care Program to assist them by providing an analytical framework for the evaluation and treatment of certain, specified health conditions. These Guidelines are not intended to replace a clinician's judgment or to establish a protocol for all patients. While the guidelines provide one approach to evaluating a medical condition, clinical conditions can be expected to vary significantly from individual to individual. Moreover, the clinical conditions delineated within the Guidelines may not match precisely with a patient's condition, and a Clinical Practice Guideline will rarely establish the only appropriate approach to a medical problem. Therefore, the clinician must exercise independent professional judgment and make decisions based upon the situation presented. While great care has been taken to assure the accuracy of the information presented, the reader is advised that Kaiser Permanente cannot be responsible for continued currency of the information, for any errors or omissions in these guidelines, or for any consequences arising from their use.

These Guidelines are protected by copyright, and unless stated otherwise, may be reproduced by users solely for their own personal, noncommercial use. Any other activity or reproduction of these documents or the information in them requires prior written permission from Kaiser Permanente. The trade names or trademarks or service marks of any of the organizations within Kaiser Permanente may not be used for any purpose.

Definition of Hypertension

The national Hypertension Guidelines Team uses the JNC7 classification of hypertension which is based on the mean of two or more properly measured seated BP readings on each of two or more office visits. The table below is modified from JNC7:

| The JNC7 Report defines blood pressure as: | Systolic Blood Pressure (SBP) mm Hg | Diastolic Blood Pressure (DBP) mm Hg |
|--|-------------------------------------|--------------------------------------|
| Normal | <120 | <80 |
| Prehypertension | 120 – 139 | 80 – 89 |
| Stage I Hypertension | 140 – 159 | 90 – 99 |
| Stage II Hypertension | ≥160 | ≥100 |

- ▶ If an individual has blood pressure of 140 to 159 mm Hg systolic, OR 90 to 99 mm Hg diastolic (Stage 1), and does not have target organ damage or diabetes mellitus, then:
 - If there is documentation of elevated blood pressure (≥ 140 mm Hg systolic, OR ≥ 90 mm Hg diastolic) for ≥ 2 to 3 months prior to the current measurement, then initiate pharmacotherapy.
 - If this is the first elevated measurement, wait approximately ≥ 2 to 3 months. After ≥ 2 to 3 months, if blood pressure is ≥ 140 mm Hg systolic, OR ≥ 90 mm Hg diastolic, then initiate pharmacotherapy.
- ▶ If an individual has blood pressure of 160 to 179 mm Hg systolic, OR 100 to 109 mm Hg diastolic (Stage 2), and does not have target organ damage or diabetes mellitus, then:
 - If there is documentation of elevated blood pressure (≥ 140 mm Hg systolic, OR ≥ 90 mm Hg diastolic) for one or more months prior to the current measurement, then initiate pharmacotherapy.
 - If this is the first elevated measurement, wait approximately one month. After one month, if blood pressure is ≥ 140 mm Hg systolic, OR ≥ 90 mm Hg diastolic, then initiate pharmacotherapy.
- ▶ If an individual has blood pressure ≥ 180 mm Hg systolic, OR ≥ 110 mm Hg diastolic, then initiate pharmacotherapy.

APPROPRIATE OFFICE-BASED TARGET BLOOD PRESSURE*

When treating an individual with hypertension, the target office blood pressure is $\leq 139 / \leq 89$ mm Hg.

When treating an individual with a prior diagnosis of stroke (excluding subarachnoid hemorrhage, subdural hematoma, and post-traumatic stroke), the target office blood pressure is $\leq 129 / \leq 79$ mm Hg for hypertension and $\leq 119 / \leq 79$ mm Hg for prehypertension.

* **NOTE:** In nonpregnant adults who do not have diabetes, heart failure, chronic kidney disease, or known coronary heart disease.

HOME BLOOD PRESSURE MONITORING FOR DIAGNOSIS AND MANAGEMENT

- ▶ It is recommended that the diagnosis of hypertension be established in the medical office.
- ▶ Home self-measurement of blood pressure is recommended to:
 - Identify a low-risk subpopulation of individuals with “white coat hypertension,” without target organ disease or diabetes, for whom medication may not be necessary. These individuals have home blood pressure levels

$\leq 134 / 84$ mm Hg but have office blood pressure levels $\geq 140 / \geq 90$ mm Hg.

- Attain control in patients with uncontrolled hypertension ($>135/85$ mm Hg by home monitoring) according to drug treatment algorithms, and by using telephone/e-mail/fax or other electronic patient communications in conjunction with standard provider-based clinic visits.
- Monitor controlled hypertension over time.
- ▶ The following quality standards are recommended for home self-measurement of blood pressure:
 - Only devices with documented yearly validation within 5 mm Hg systolic and 5 mm Hg diastolic of a blood pressure measure by a nurse, physician, or trained observer are acceptable, preferably those devices approved by Association for the Advancement of Medical Instrumentation, British Hypertension Society, or European Hypertension Society.
 - Devices with visual or printout memory or using telemonitoring are preferred.
 - Eligible patients should have observation of blood pressure competency, with particular attention to miscuffing and common pitfalls of technique during yearly validation. Only brachial pressures are acceptable.
 - A minimum of six home blood pressures should be used, half of which were obtained in the morning.
 - Control by home blood pressure monitoring is defined as a mean of $\leq 134 / 84$ mm Hg.
 - Since no home blood pressure equivalency for an office blood pressure of $< 129 / 79$ mm Hg has been demonstrated in the literature, home blood pressure should not be used exclusively as a surrogate in the care of patients with diabetes or chronic kidney disease with a targeted office blood pressure $\leq 129 / 79$ mm Hg.

FIRST-LINE TREATMENT OF HYPERTENSION

Thiazide diuretics (either as a single agent or in combination) are strongly recommended as first-line agents for initial therapy in people with hypertension.

INITIAL COMBINATION TREATMENT OF HYPERTENSION*

- ▶ Combination therapy consisting of a thiazide diuretic plus an ACEI is an option for initial therapy for Stage 1 hypertension (systolic blood pressure 140 to 159 mm Hg, OR diastolic blood pressure 90 to 99 mm Hg).
- ▶ Combination therapy of a thiazide diuretic plus an ACEI is recommended for Stage 2 hypertension (systolic blood pressure > 160 mm Hg, OR diastolic blood pressure > 100 mm Hg).

* **NOTE:** In non-pregnant adults who do not have diabetes, heart failure, chronic kidney disease, or known coronary heart disease.

STEP-CARE THERAPY FOR HYPERTENSION

Because most people with hypertension will need more than one drug to control their hypertension effectively:

- ▶ **For two drugs:** If blood pressure is not controlled on a thiazide-type diuretic alone, then a thiazide-type diuretic plus ACEI is recommended.
- ▶ **For three drugs:** If blood pressure is not controlled on a thiazide-type diuretic + ACEI, then a thiazide-type diuretic plus ACEI plus dihydropyridine calcium channel blocker is recommended.
- ▶ **For four drugs:** If blood pressure is not controlled on a thiazide-type diuretic plus ACEI plus dihydropyridine calcium channel blocker, then a thiazide-type diuretic plus ACEI plus dihydropyridine calcium channel blocker plus beta-blocker is recommended.

DISCRETE POPULATIONS HYPERTENSION TREATMENT FOR WOMEN OF CHILDBEARING POTENTIAL

- ▶ ACEIs are contraindicated in pregnancy.
- ▶ ACEIs are not recommended for women of childbearing potential who are not practicing highly effective contraceptive measures (IUD or sustained hormone delivery systems).
- ▶ It is recommended that women of childbearing potential with a compelling indication for ACEIs* be warned of possible fetal risk and instructed to use highly effective contraception while continuing to use the ACEI.

* **NOTE:** Compelling indications for ACEIs include heart failure with systolic dysfunction, diabetes mellitus with microalbuminuria, diabetes mellitus with nephropathy, and nondiabetic proteinuria.

DISCRETE POPULATIONS POST-STROKE TREATMENT OF HYPERTENSION

Combination therapy with a thiazide diuretic plus an ACE inhibitor is recommended as initial treatment for patients who are post-stroke or post-TIA* with hypertension or prehypertension.

* **NOTE:** Transient ischemic attack (TIA) is defined as evidence of an acute disturbance of focal neurological or monocular function with symptoms lasting less than 24 hours thought to be due to arterioembolic or thrombotic vascular disease.

BEHAVIORAL CHANGE SUPPLEMENTARY TREATMENT OF

UNCOMPLICATED HYPERTENSION WITH LIFESTYLE MODIFICATIONS

- ▶ A moderately low-sodium, low-fat diet with a high intake of fruits and vegetables (DASH diet) is recommended to supplement pharmacotherapy for patients with hypertension.
- ▶ Weight reduction is recommended for patients with a BMI ≥ 25 kg/m² on antihypertensive medications.
- ▶ It is recommended that hypertension patients who consume alcohol have no more than one alcoholic drink (for women) or two alcoholic drinks (for men) daily.
- ▶ Physical activity (at least 30 minutes of walking or equivalent at least three times per week) is recommended for patients with hypertension who are on medications.

BEHAVIORAL CHANGE ADHERENCE TO MEDICATIONS AND LIFESTYLE MODIFICATIONS

The following are recommended:

- ▶ Assist patients to achieve medication and lifestyle adherence by means of a vigorous step-care approach to therapy and an organized system of regular medical follow-up and review.
- ▶ Once-daily medication and combination therapy whenever possible.
- ▶ Address issues of depression and anxiety issues in order to maximize patient adherence.
- ▶ Use patient education in conjunction with other strategies, particularly in the context of team care utilizing nurses and pharmacists.
- ▶ Educate patients about their goal pressure because patients who are knowledgeable about their goal blood pressure are more likely to achieve it.

Use of Aspirin in Hypertensive Patients Receiving Antihypertensive Medications

FOR PRIMARY CVD PROPHYLAXIS

In the absence of known CAD, stroke or diabetes mellitus:

- ▶ When the CHD risk is high, low-dose aspirin (81 mg daily) is recommended. A shared decision-making approach, with a review of the benefits and harms, is recommended.
- ▶ For individuals with an intermediate risk of CHD, low-dose aspirin (81 mg daily) is an option. Use of aspirin should be based on a shared decision-making approach and on each individual's benefit/risk* status.

- ▶ When the CHD risk is low, aspirin is not recommended. For low-risk patients who are already taking aspirin, or who express a desire to begin taking it, a shared decision-making approach, with a review of the benefits and harms, is recommended.
- ▶ Aspirin is not recommended for patients with uncontrolled hypertension.
 - * **NOTE:** The benefit for men is primarily reduction in nonfatal MI and the benefit for women is stroke reduction. Low-dose aspirin increases the risk of GI bleeding and hemorrhagic stroke, and the risk of hemorrhagic stroke may increase with uncontrolled hypertension, particularly Stage 2 hypertension. NNTs to prevent one adverse CV outcome vs NNHs (usually a GI bleed requiring transfusion) for men and women on low-dose aspirin for primary CV prophylaxis for 6.4 years are: women NNT = 333 and NNH = 400; men: NNT = 270 and NNH = 303.

Use of Antilipemic Therapy in Hypertensive Patients Taking Antihypertensive Medications

No recommendation for or against the use of antilipemic therapy in hypertensive patients in the absence of other significant risk factors.

Patients with hypertension should be treated for hyperlipidemia according to their total cardiovascular risk profile.